| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1026008277 |
| P356 | DOI | 10.2165/00002018-200427010-00003 |
| P8608 | Fatcat ID | release_l6r5hucqdzc47jfcmenlkwoisu |
| P3181 | OpenCitations bibliographic resource ID | 59326 |
| P698 | PubMed publication ID | 14720085 |
| P50 | author | Nicholas John White | Q21166848 |
| P2093 | author name string | W Robert J Taylor | |
| P2860 | cites work | Clinical studies on the treatment of malaria with qinghaosu and its derivatives. China Cooperative Research Group on qinghaosu and its derivatives as antimalarials | Q56501803 |
| Stevens-Johnson syndrome after mass prophylaxis with sulfadoxine for cholera in Mozambique | Q62494485 | ||
| The 1991 Persian Gulf War: Implications for Biological Arms Control | Q67479657 | ||
| Halofantrine overdosage | Q68053667 | ||
| Practical chemotherapy of malaria. Report of a WHO Scientific Group | Q68378577 | ||
| [Cutaneous reactions appearing during the mass prophylaxis of cerebrospinal meningitis with a long-delayed action sulfonamide (apropos of 997 cases)] | Q68433467 | ||
| Fatal quinine-induced thrombocytopenia | Q68696795 | ||
| Sulfonamide-induced chronic liver disease | Q68882988 | ||
| Lichen planus in a photosensitive distribution due to quinine | Q69510054 | ||
| Fetal toxoplasmosis: outcome of pregnancy and infant follow-up after in utero treatment | Q69550872 | ||
| Therapeutic responses to different antimalarial drugs in vivax malaria | Q24550626 | ||
| Side effect of quinine for nocturnal cramps | Q24645952 | ||
| Assessment of the pharmacodynamic properties of antimalarial drugs in vivo | Q24670346 | ||
| Quinine-induced cutaneous vasculitis | Q28317652 | ||
| Aplasia and leukaemia following chloroquine therapy | Q28323659 | ||
| Systemic quinine photosensitivity | Q69584893 | ||
| Severe cutaneous adverse reactions to sulfadoxine-pyrimethamine in Switzerland | Q69877882 | ||
| Liver damage associated with fansidar | Q69879314 | ||
| Leads from the MMWR. Adverse reactions to Fansidar and updated recommendations for its use in the prevention of malaria | Q69882026 | ||
| Fansidar and hepatic granulomas | Q70082734 | ||
| Persistent light reactivity from systemic quinine | Q70244018 | ||
| Amodiaquine ocular changes | Q70422223 | ||
| Megaloblastic anemia and pancytopenia due to Proguanil in patients with chronic renal failure | Q70509185 | ||
| Chloroquine and psoriasis | Q70717072 | ||
| Ocular quinine toxicity | Q71348102 | ||
| The critical period of pyrimethamine teratogenesis in the rat | Q71436036 | ||
| Aberrant atrioventricular conduction triggered by antimalarial prophylaxis with mefloquine | Q71975998 | ||
| Stevens-Johnson syndrome following the use of an ultra-long-acting sulphonamide | Q72065333 | ||
| Sensitivity to primaquine in Ceylonese children due to deficiency of erythrocytic glucose-6-phosphate dehydrogenase | Q72218816 | ||
| Nature of Hemolytic Crises and the Fate of G6PD Deficient, Drug-Damaged Erythrocytes in Sardinians | Q72219112 | ||
| Pyrimethamine combinations in pregnancy | Q72564870 | ||
| Toxic epidermal necrolysis due to chloroquine phosphate | Q72695583 | ||
| Fatal neurotoxicity of arteether and artemether | Q72762742 | ||
| Quinine-induced hypoglycemia | Q72810366 | ||
| Halofantrine-associated ventricular fibrillation in a young woman with no predisposing QTc prolongation | Q73411193 | ||
| Daraprim as an antagonist of folic and folinic acids | Q74026428 | ||
| A 15 month controlled study of the effects of amodiaquine (camoquin) in rheumatoid arthritis | Q79153284 | ||
| Quinine and congenital injuries of ear and eye of the foetus | Q79559201 | ||
| Comparison of artemether and quinine in the treatment of severe falciparum malaria in south-east Thailand | Q39121176 | ||
| Clinical pharmacokinetics of halofantrine | Q39121208 | ||
| Clinical and neurophysiological study of the effects of multiple doses of artemisinin on brain-stem function in Vietnamese patients | Q39139333 | ||
| Malaria as a reemerging disease | Q39148905 | ||
| Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children | Q39170296 | ||
| Monitoring for mefloquine-resistant Plasmodium falciparum in Africa: implications for travelers' health | Q39186539 | ||
| A randomized, double-blind, comparative trial of a new oral combination of artemether and benflumetol (CGP 56697) with mefloquine in the treatment of acute Plasmodium falciparum malaria in Thailand. | Q39188476 | ||
| The effects of quinine and chloroquine antimalarial treatments in the first trimester of pregnancy | Q39234325 | ||
| Pharmacokinetic and pharmacodynamic interactions of mefloquine and quinine | Q39288406 | ||
| Post-malaria neurological syndrome | Q39302539 | ||
| Assessment of the neurotoxicity of parenteral artemisinin derivatives in mice | Q39308526 | ||
| Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study | Q39309831 | ||
| Malaria during pregnancy in an area of unstable endemicity | Q39309866 | ||
| Controlling malaria: challenges and solutions | Q39322857 | ||
| Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy. | Q39354389 | ||
| The safety of antimalarial drugs in pregnancy | Q39354397 | ||
| Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand | Q39370966 | ||
| Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria | Q39370997 | ||
| Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial | Q39460339 | ||
| Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. | Q39489358 | ||
| Malaria parasite infection during pregnancy and at delivery in mother, placenta, and newborn: efficacy of chloroquine and mefloquine in rural Malawi. | Q39489373 | ||
| Mefloquine and sulfadoxine/pyrimethamine overdose in malaria tropica | Q39496496 | ||
| A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia | Q39497023 | ||
| Lack of a significant adverse cardiovascular effect of combined quinine and mefloquine therapy for uncomplicated malaria | Q39499357 | ||
| Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria | Q39517603 | ||
| Electrocardiographic changes and halofantrine plasma level during acute falciparum malaria. | Q39531255 | ||
| A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria | Q39532225 | ||
| Blackwater fever in southern Vietnam: a prospective descriptive study of 50 cases | Q39532229 | ||
| The comparative efficacy and tolerability of CGP 56697 (artemether + lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the Tropics to The Netherlands and France | Q39546953 | ||
| Recurrence of blackwater fever: triggering of relapses by different antimalarials | Q39548628 | ||
| Neuro-psychiatric effects of antimalarials | Q39551761 | ||
| Increased prevalence of malaria in HIV-infected pregnant women and its implications for malaria control | Q39558033 | ||
| An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi | Q39558050 | ||
| Malaria chemoprophylaxis in travellers to east Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulfadoxine-pyrimethamine | Q36894866 | ||
| Meta-analysis of efficacy of quinine for treatment of nocturnal leg cramps in elderly people | Q36901785 | ||
| Plasma protein binding of drugs in pregnancy and in neonates | Q37905436 | ||
| Quinine hepatotoxicity. An underrecognized or rare phenomenon? | Q38073329 | ||
| Guidelines for malaria prevention in travellers from the United Kingdom for 2001. | Q38577465 | ||
| Adverse effects and compliance with mefloquine or proguanil antimalarial chemoprophylaxis | Q38579329 | ||
| Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug | Q38618588 | ||
| Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial | Q38883517 | ||
| Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial | Q38885032 | ||
| Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria | Q38891258 | ||
| Electrocardiographic monitoring in severe falciparum malaria | Q38906780 | ||
| Fatal quinine cardiotoxicity in the treatment of falciparum malaria | Q38914307 | ||
| Atovaquone plus proguanil versus halofantrine for the treatment of imported acute uncomplicated Plasmodium falciparum malaria in non-immune adults: a randomized comparative trial. | Q38916563 | ||
| Clinical efficacy and pharmacokinetics of micronized halofantrine for the treatment of acute uncomplicated falciparum malaria in nonimmune patients. | Q38916577 | ||
| High dose of primaquine in primaquine resistant vivax malaria | Q38925712 | ||
| Fansimef for prophylaxis of malaria: a double-blind randomized placebo controlled trial | Q38925735 | ||
| Frequency of pruritus in Plasmodium vivax malaria patients treated with chloroquine in Thailand | Q38926999 | ||
| Atovaquone-proguanil compared with chloroquine and chloroquine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines | Q38927109 | ||
| Quinine pharmacokinetics: ototoxic and cardiotoxic effects in healthy Caucasian subjects and in patients with falciparum malaria | Q38947717 | ||
| Primaquine resistance in Plasmodium vivax | Q38950998 | ||
| Treatment of Plasmodium vivax malaria--time for a change? | Q38975166 | ||
| Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years | Q39056417 | ||
| Averting a malaria disaster | Q39118502 | ||
| Delayed cerebellar ataxia complicating falciparum malaria: a clinical study of 74 patients | Q40700518 | ||
| Intravascular haemolysis following halofantrine intake | Q40706923 | ||
| A new micronized formulation of halofantrine hydrochloride in the treatment of acute Plasmodium falciparum malaria | Q40716229 | ||
| Adverse drug reactions: definitions, diagnosis, and management | Q40739350 | ||
| Evaluation of the clinical efficacy and safety of halofantrine in falciparum malaria in Ibadan, Nigeria | Q40758613 | ||
| Tolerability of prophylactic Lariam regimens. | Q40787768 | ||
| A double-blind trial of a fixed combination of mefloquine plus sulfadoxine-pyrimethamine compared with sulfadoxine-pyrimethamine alone in symptomatic falciparum malaria. | Q40801791 | ||
| Recurrent pancytopenia, coagulopathy, and renal failure associated with multiple quinine-dependent antibodies | Q40821492 | ||
| A double-blind comparative clinical trial of mefloquine and chloroquine in symptomatic falciparum malaria | Q40839999 | ||
| Adverse effects of antimalarials. An update | Q40901285 | ||
| Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Piasmodium vivax by intermittent regimens of drug administration: a preliminary report | Q41001278 | ||
| Antimalarial drugs in the treatment of rheumatological diseases | Q41560764 | ||
| Drug-associated hemolytic anemia. | Q41832967 | ||
| Unusual pulmonary reaction during short term prophylaxis with pyrimethamine-sulfadoxine (Fansidar). | Q41841921 | ||
| Examination of some factors responsible for a food-induced increase in absorption of atovaquone | Q41907361 | ||
| Treatment of severe chloroquine poisoning | Q41912431 | ||
| In vitro drug response of Plasmodium falciparum in the Philippines: increased resistance to amodiaquine | Q41913641 | ||
| Amodiaquine less effective than chloroquine in the treatment of falciparum malaria in the Philippines | Q41914364 | ||
| Fatal Stevens-Johnson syndrome associated with Fansidar and chloroquine | Q41915261 | ||
| Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. | Q41915538 | ||
| Erythroderma resembling sézary syndrome after treatment with Fansidar and chloroquine. | Q41915552 | ||
| Tolerability of long-term prophylaxis with fansidar: a randomized double-blind study in Nigeria | Q41918183 | ||
| Pharmacokinetics of chloroquine in renal insufficiency | Q41918705 | ||
| Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team | Q41920606 | ||
| An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug | Q41920635 | ||
| Amodiaquine remains effective for treating uncomplicated malaria in west and central Africa | Q41922065 | ||
| Hydroxychloroquine in psoriatic arthropathy: exacerbations of psoriatic skin lesions. | Q41923213 | ||
| Bullous pemphigoid developing during systemic therapy with chloroquine | Q41923404 | ||
| Double-blind, randomized, placebo-controlled assessment of chloroquine/primaquine prophylaxis for malaria in nonimmune Colombian soldiers | Q41923565 | ||
| The treatment of malaria in glucose-6-phosphate dehydrogenase deficient patients in Sabah | Q41924144 | ||
| Antimalarial prophylaxis--use and adverse events in visitors to the Kruger National Park | Q41924359 | ||
| Is halofantrine still advisable in malaria attacks? | Q41926303 | ||
| Compliance with and tolerance of mefloquine and chloroquine + proguanil malaria chemoprophylaxis in French short-term travellers to sub-Saharan Africa | Q41927593 | ||
| An unusual reaction to chloroquine-primaquine | Q41931155 | ||
| Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil | Q41932952 | ||
| The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. | Q41934399 | ||
| Methaemoglobin levels in soldiers receiving antimalarial drugs | Q41937061 | ||
| Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. | Q41937668 | ||
| Long-term malaria prophylaxis with weekly mefloquine | Q41937874 | ||
| In vitro activity of monodesethylamodiaquine and amopyroquine against African isolates and clones of Plasmodium falciparum. | Q41938674 | ||
| Mefloquine-sulphadoxine-pyrimethamine (Fansimef®, Roche) in the prophylaxis ofPlasmodium falciparummalaria: a double-blind, comparative, placebo-controlled study | Q41939138 | ||
| Chloroquine therapy in psoriatic arthritis | Q41939226 | ||
| Quinine treatment of severe falciparum malaria in African children: a randomized comparison of three regimens | Q41941225 | ||
| Exacerbation of psoriasis caused by malaria prophylaxis with chloroquine and proguanil | Q41942163 | ||
| Chloroquine-induced pruritus: its impact on chloroquine utilization in malaria control in Dar es Salaam | Q41942506 | ||
| The concurrent weekly administration of chloroquine and primaquine for the prevention of Korean vivax malaria | Q41945775 | ||
| Amodiaquine-induced hepatitis. A report of seven cases | Q42201604 | ||
| Fatal hepatic necrosis due to pyrimethamine-sulfadoxine (Fansidar). | Q42203852 | ||
| Pharmacokinetics and clinical toxicity of quinine overdosage: lack of efficacy of techniques intended to enhance elimination | Q42227498 | ||
| Clinical observations of ocular quinine intoxication | Q42251378 | ||
| Acute intravascular haemolysis due to quinine | Q42261195 | ||
| Cardiac complications of halofantrine: a prospective study of 20 patients | Q42276310 | ||
| Pharmacokinetics of halofantrine in man: effects of food and dose size | Q42285069 | ||
| Tolerance of mefloquine by SwissAir trainee pilots | Q42550727 | ||
| Atrial flutter with 1:1 conduction after administration of the antimalarial drug mefloquine. | Q42551967 | ||
| Tolerance of mefloquine chemoprophylaxis in Dutch military personnel | Q42554421 | ||
| Blindness from quinine as an antimalarial | Q42554716 | ||
| Dapsone- and primaquine-induced methemoglobinemia in HIV-infected individuals | Q42554723 | ||
| Cardiac effects of standard-dose halofantrine therapy | Q42556956 | ||
| Severe megaloblastic anemia complicating pyrimethamine therapy | Q42565403 | ||
| Malaria prophylaxis and epilepsy | Q42712417 | ||
| Better standards for better reporting of RCTs | Q42772336 | ||
| The Thai-Burmese border: drug studies of Plasmodium falciparum in pregnancy | Q43506299 | ||
| Mefloquine-induced acute hepatitis | Q43513507 | ||
| Blackwater fever after ingestion of mefloquine. Three cases | Q43580013 | ||
| Quinine-induced thrombocytopenia in a 64-year-old man who consumed tonic water to relieve nocturnal leg cramps | Q43703706 | ||
| Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity. A randomized, double-blind, placebo-controlled trial. | Q43726653 | ||
| Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases | Q43743058 | ||
| The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy | Q43752865 | ||
| Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model | Q43752867 | ||
| Danger of malaria self-treatment. Acute neurologic toxicity of mefloquine and its combination with pyrimethamine-sulfadoxine | Q43776273 | ||
| Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate | Q43798145 | ||
| Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum | Q43801610 | ||
| The effects of mefloquine treatment in pregnancy | Q43964798 | ||
| Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial | Q43972330 | ||
| Quinine--acute self-poisoning and ocular toxicity | Q44409074 | ||
| Artemisinin derivatives in the treatment of falciparum malaria in pregnancy | Q44514584 | ||
| The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria | Q44573293 | ||
| In vivo efficacy of mefloquine for the treatment of Falciparum malaria in Brazil | Q44597437 | ||
| Proguanil, chloroquine, and mouth ulcers | Q44748748 | ||
| Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria | Q45161148 | ||
| Acute renal failure, acute rhabdomyolysis and falciparum malaria | Q45207139 | ||
| Antimalarial agents in pregnancy | Q45712596 | ||
| Neuropsychiatric side effects of mefloquine in Africans | Q46165432 | ||
| Halofantrine in the treatment of uncomplicated falciparum malaria with a three-dose regimen in Papua New Guinea: a preliminary report | Q46176356 | ||
| Pruritus and antimalarial drugs in Africans | Q46331776 | ||
| Quinine pharmacokinetics in young children with severe malaria. | Q46345860 | ||
| A study of maternal mortality at the University Teaching Hospital, Lusaka, Zambia: the emergence of tuberculosis as a major non-obstetric cause of maternal death | Q46356031 | ||
| Mefloquine or doxycycline prophylaxis in US troops in Somalia | Q46359876 | ||
| Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study | Q46364500 | ||
| A randomized safety and tolerability trial of artesunate plus sulfadoxine--pyrimethamine versus sulfadoxine-pyrimethamine alone for the treatment of uncomplicated malaria in Gambian children. | Q46365105 | ||
| Arteether-induced brain injury in Macaca mulatta. I. The precerebellar nuclei: the lateral reticular nuclei, paramedian reticular nuclei, and perihypoglossal nuclei. | Q46407268 | ||
| Comparison of intramuscular and intravenous quinine for the treatment of severe and complicated malaria in children. | Q46427011 | ||
| A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children | Q46610802 | ||
| Halofantrine and acute intravascular haemolysis | Q46919159 | ||
| Post-marketing surveillance of prophylactic mefloquine (Lariam) use in pregnancy. | Q47825692 | ||
| Cardiac effects of halofantrine in children suffering from acute uncomplicated falciparum malaria | Q47840842 | ||
| Early vomiting of mefloquine in children with malaria is not modified by the timing of antipyretic treatment | Q47841164 | ||
| Quinine and mefloquine in the treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy | Q47842564 | ||
| No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine | Q47858942 | ||
| The management of porphyria cutanea tarda | Q33952683 | ||
| Toxicity of primaquine in Caucasians | Q33975955 | ||
| Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria. | Q33976068 | ||
| Methemoglobinemia Provoked by Malarial Chemoprophylaxis in Vietnam | Q34054065 | ||
| Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy | Q34058524 | ||
| CNS adverse events associated with antimalarial agents. Fact or fiction? | Q34062133 | ||
| Adverse reactions to sulphadoxine-pyrimethamine in Swedish travellers: implications for prophylaxis | Q34071371 | ||
| High incidence of hypoglycaemia in African patients treated with intravenous quinine for severe malaria | Q34072288 | ||
| Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study | Q34088738 | ||
| Amodiaquine induced agranulocytosis and liver damage. | Q34284638 | ||
| Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. | Q34288516 | ||
| Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria | Q34358656 | ||
| Atovaquone plus proguanil is an effective treatment for Plasmodium ovale and P. malariae malaria | Q34414994 | ||
| Excretion of chloroquine and desethylchloroquine in human milk | Q34416343 | ||
| Ocular quinine toxicity treated with hyperbaric oxygen | Q34427786 | ||
| Quinine pharmacokinetics and toxicity in pregnant and lactating women with falciparum malaria | Q34447502 | ||
| Excretion of chloroquine, dapsone and pyrimethamine in human milk | Q34448267 | ||
| Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. | Q34482190 | ||
| Safety of chloroquine in chemosuppression of malaria during pregnancy | Q34484612 | ||
| Adverse reactions to sulfa drugs: implications for malaria chemotherapy | Q34860367 | ||
| Drug resistant malaria, with special reference to Thailand | Q35220189 | ||
| Self-administration of medicaments. A review of published work and a study of the problems | Q35355626 | ||
| Mefloquine to prevent malaria: a systematic review of trials | Q36247393 | ||
| Mefloquine therapy for Plasmodium falciparum malaria in children under 5 years of age in Malawi: in vivo/in vitro efficacy and correlation of drug concentration with parasitological outcome | Q36668481 | ||
| Malaria chemoprophylaxis among European tourists in tropical Africa: use, adverse reactions, and efficacy | Q36668633 | ||
| Toxicology of the 8-aminoquinolines and genetic factors associated with their toxicity in man. | Q36675502 | ||
| Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. | Q36687375 | ||
| Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine | Q36706126 | ||
| A review of randomized controlled trials of routine antimalarial drug prophylaxis during pregnancy in endemic malarious areas | Q36794206 | ||
| Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia | Q36852726 | ||
| Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial | Q36865242 | ||
| Ophthalmological monitoring for hydroxychloroquine toxicity: a scientific review of available data | Q36866245 | ||
| A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand | Q36874970 | ||
| Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial | Q39564872 | ||
| The treatment of malaria | Q39590029 | ||
| Can amodiaquine be resurrected? | Q39590039 | ||
| Chloroquine treatment of severe malaria in children. Pharmacokinetics, toxicity, and new dosage recommendations | Q39590150 | ||
| Role of quinine in the high mortality of intramuscular injection tetanus | Q39615778 | ||
| Blindness from quinine toxicity | Q39635568 | ||
| Clinical features and management of poisoning due to antimalarial drugs | Q39667043 | ||
| The chemistry, pharmacology, and clinical applications of qinghaosu (artemisinin) and its derivatives | Q39762126 | ||
| Glucose-6-phosphate dehydrogenase deficiency: a brief review | Q40039268 | ||
| Use of quinine for self-induced abortion. | Q40272785 | ||
| Antimalarial agents. Chloroquine, hydroxychloroquine, and quinacrine | Q40283976 | ||
| New Antimalarials A Risk-Benefit Analysis | Q40466095 | ||
| Incidence of myopathy in patients treated with antimalarials. A report of three cases and a review of the literature | Q40499065 | ||
| A randomized, double-blind, parallel-group, comparative safety, and efficacy trial of oral co-artemether versus oral chloroquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in India. | Q40613394 | ||
| Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria | Q40636345 | ||
| Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria | Q40678104 | ||
| An etiologic study of hemoglobinuria and blackwater fever in the Kivu Mountains, Zaire | Q40687883 | ||
| Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions | Q47860426 | ||
| Mefloquine for multidrug-resistant malaria | Q47862664 | ||
| Inefficacy of amodiaquine against chloroquine-resistant malaria | Q47862721 | ||
| A case-control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria. | Q47863256 | ||
| Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant falciparum malaria in pregnancy | Q47866114 | ||
| Fatal cardiac incident after use of halofantrine | Q47871854 | ||
| Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers | Q47872121 | ||
| Drug-protein conjugates--XVIII. Detection of antibodies towards the antimalarial amodiaquine and its quinone imine metabolite in man and the rat. | Q47888410 | ||
| Stevens-Johnson syndrome due to pyrimethamine/sulfadoxine during presumptive self-therapy of malaria | Q47890642 | ||
| Follow-up observation on the therapeutic effects and remote reactions of artemisinin (Qinghaosu) and artemether in treating malaria in pregnant woman | Q47898161 | ||
| Quinine and severe falciparum malaria in late pregnancy | Q47899455 | ||
| Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria | Q47899792 | ||
| Excretion of mefloquine in human breast milk | Q47910186 | ||
| Treatment of imported cases of falciparum malaria in France with halofantrine | Q47921265 | ||
| Fansidar hypersensitivity pneumonitis | Q47923274 | ||
| Accidental overdose of pyrimethamine and sulphadoxine for malaria prophylaxis without adverse effects | Q47924986 | ||
| Relapse of vivax malaria treated with primaquine and report of one case of cyanosis (methemoglobinemia) due to primaquine. | Q47941339 | ||
| The haemolytic effect of a single dose of 45 mg of primaquine in G-6-PD deficient Thais | Q47941757 | ||
| The effect of continuous and intermittent primaquine therapy on the relapse rate of Chesson strain vivax malaria. | Q47944175 | ||
| Serious reactions during malaria prophylaxis with pyrimethamine-sulfadoxine. | Q47972510 | ||
| Teratogenicity of pyrimethamine | Q47972850 | ||
| Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. | Q47974048 | ||
| Quinine Loading Dose in Cerebral Malaria * | Q47975941 | ||
| Severe Hypoglycemia and Hyperinsulinemia in Falciparum Malaria | Q47976600 | ||
| Why are primaquine and other 8-aminoquinolines particularly effective against the mature gametocytes and the hypnozoites of malaria? | Q47979380 | ||
| Toxicity of primaquine in Negroes | Q47980324 | ||
| Mefloquine resistance in Plasmodium falciparum | Q47990008 | ||
| Effects of low concentrations of pyrimethamine on human bone marrow cells in vitro: possible implications for malaria prophylaxis | Q47996474 | ||
| Acute intravascular haemolysis in glucose-6-phosphate dehydrogenase deficiency | Q47998751 | ||
| Optimal regimens of parenteral quinine | Q48000492 | ||
| Towards optimal regimens of parenteral quinine for young African children with cerebral malaria: unbound quinine concentrations following a simple loading dose regimen | Q48011218 | ||
| Fast emergence of Plasmodium falciparum resistance to halofantrine | Q48013805 | ||
| Cardiac effects of antimalarial treatment with halofantrine | Q48013877 | ||
| Amplification of quinine cardiac effects by the resistance-reversing agent prochlorperazine in falciparum malaria | Q48018322 | ||
| Long-term malaria chemoprophylaxis with mefloquine in Dutch marines in Cambodia | Q48027629 | ||
| Atovaquone and proguanil for Plasmodium falciparum malaria | Q48028627 | ||
| An open randomized trial of artemether versus quinine in the treatment of cerebral malaria in African children | Q48030403 | ||
| Mefloquine in infants and young children | Q48035075 | ||
| Plasmodium vivax infections in U.S. Army troops: failure of primaquine to prevent relapse in studies from Somalia. | Q48036375 | ||
| Ataxia and slurred speech after artesunate treatment for falciparum malaria | Q48036625 | ||
| The effects of inadvertent exposure of mefloquine chemoprophylaxis on pregnancy outcomes and infants of US Army servicewomen | Q48037359 | ||
| Pustular eruption in a malaria patient treated with chloroquine | Q48037480 | ||
| Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697. | Q48037496 | ||
| Behavioral and neural toxicity of arteether in rats | Q48445818 | ||
| Effects of mefloquine alone and with alcohol on psychomotor and driving performance | Q49128771 | ||
| Bitter lemon purpura | Q49806370 | ||
| Mefloquine Prophylaxis and Hearing, Postural Control, and Vestibular Functions. | Q50519431 | ||
| Complications of quinine poisoning. | Q51830739 | ||
| Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. | Q54331638 | ||
| World malaria situation in 1994. Part I. Population at risk | Q56451885 | ||
| Neuropsychiatric side effects after the use of mefloquine | Q28327454 | ||
| Quinine induces reversible high-tone hearing loss | Q28331125 | ||
| Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine | Q28334029 | ||
| Quinine-induced disseminated intravascular coagulation | Q28334464 | ||
| Amodiaquine-induced involuntary movements | Q28334568 | ||
| Acute, persistent quinine-induced blindness. A case report | Q28335552 | ||
| Recurrent acute hypersensitivity to quinine | Q28335935 | ||
| Convulsions associated with prophylactic antimalarial drugs: implications for people with epilepsy | Q28361046 | ||
| Fatal multisystemic toxicity associated with prophylaxis with pyrimethamine and sulfadoxine (Fansidar). | Q28361116 | ||
| Death and blindness due to overdose of quinine | Q28362362 | ||
| Dermatological adverse effects with the antimalarial drug mefloquine: a review of 74 published case reports | Q28371403 | ||
| Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers | Q28379101 | ||
| Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients | Q28379200 | ||
| Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster | Q29614923 | ||
| A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria | Q30671063 | ||
| Therapy of uncomplicated falciparum malaria: a randomized trial comparing artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone in Irian Jaya, Indonesia. | Q30761314 | ||
| Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia | Q30847884 | ||
| Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia | Q31030931 | ||
| Drug-induced blood dyscrasias. A ten-year material from the Swedish Adverse Drug Reaction Committee | Q33464310 | ||
| Drug-induced blood disorders | Q33475829 | ||
| Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature | Q33491281 | ||
| Multiple quinine-dependent antibodies in a patient with episodic thrombocytopenia, neutropenia, lymphocytopenia, and granulomatous hepatitis | Q33500990 | ||
| Neurotoxicity and artemisinin compounds do the observations in animals justify limitation of clinical use? | Q33599534 | ||
| Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials | Q33599550 | ||
| Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group | Q33646960 | ||
| Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives | Q33646966 | ||
| Mefloquine for malaria chemoprophylaxis 1992-1998: a review. | Q33669693 | ||
| Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. | Q33690621 | ||
| Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. | Q33749505 | ||
| Triggered psoriasis | Q33795048 | ||
| Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand | Q33863520 | ||
| Effect of home-based neonatal care and management of sepsis on neonatal mortality: field trial in rural India | Q33885650 | ||
| Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand | Q33893391 | ||
| Severe allergic reactions to oral artesunate: a report of two cases | Q33946965 | ||
| P433 | issue | 1 | |
| P921 | main subject | malaria | Q12156 |
| antimalarial | Q521616 | ||
| P304 | page(s) | 25-61 | |
| P577 | publication date | 2004-01-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Antimalarial Drug Toxicity | |
| P478 | volume | 27 |
| Q90863454 | 8-Aminoquinolines with an Aminoxyalkyl Side Chain Exert in vitro Dual-Stage Antiplasmodial Activity |
| Q35203887 | A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania |
| Q33693580 | A controlled trial to assess the effect of quinine, chloroquine, amodiaquine, and artesunate on Loa loa microfilaremia |
| Q47991392 | A genome-wide screen identifies yeast genes required for protection against or enhanced cytotoxicity of the antimalarial drug quinine |
| Q35038613 | A study of toxicity and differential gene expression in murine liver following exposure to anti-malarial drugs: amodiaquine and sulphadoxine-pyrimethamine |
| Q38928995 | Amodiaquine dosage and tolerability for intermittent preventive treatment to prevent malaria in children |
| Q37293982 | Amodiaquine pharmacogenetics |
| Q43124090 | Amodiaquine-induced toxicity in isolated rat hepatocytes and the cytoprotective effects of taurine and/or N-acetyl cysteine |
| Q42488257 | Anticancer agents against malaria: time to revisit? |
| Q36717631 | Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. |
| Q33806574 | Antimalarial drugs and the prevalence of mental and neurological manifestations: A systematic review and meta-analysis. |
| Q36734794 | Antimalarial drugs inhibit human 5-HT(3) and GABA(A) but not GABA(C) receptors |
| Q90401606 | Antiproliferative chromone derivatives induce K562 cell death through endogenous and exogenous pathways |
| Q42706335 | Artemether and artesunate show the highest efficacies in rescuing mice with late-stage cerebral malaria and rapidly decrease leukocyte accumulation in the brain |
| Q37388596 | Artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria |
| Q46184684 | Artemisinin induces hormonal imbalance and oxidative damage in the erythrocytes and uterus but not in the ovary of rats. |
| Q24236067 | Artemisinin-based combination therapy for the treatment of uncomplicated Plasmodium vivax malaria and the prevention of relapses |
| Q24202910 | Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria |
| Q24235351 | Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria |
| Q42845988 | Artemisinins inhibit Trypanosoma cruzi and Trypanosoma brucei rhodesiense in vitro growth |
| Q34675798 | Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production |
| Q57014040 | Artesunate versus quinine for severe falciparum malaria – Authors' reply |
| Q36861619 | Artesunate-amodiaquine for the treatment of uncomplicated malaria |
| Q30478626 | Artesunate-mefloquine combination therapy in acute Plasmodium falciparum malaria in young children: a field study regarding neurological and neuropsychiatric safety |
| Q36945007 | Assessment of safety of the major antimalarial drugs |
| Q89254349 | Associations between Use of Antimalarial Medications and Health among U.S. Veterans of the Wars in Iraq and Afghanistan |
| Q34233691 | Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity |
| Q41913205 | Attenuation of chloroquine-induced renal damage by alpha-lipoic acid: possible antioxidant mechanism |
| Q24234168 | Azithromycin for treating uncomplicated malaria |
| Q36717625 | Case management of malaria in pregnancy |
| Q41941401 | Changes in antioxidant status and biochemical indices after acute administration of artemether, artemether-lumefantrine and halofantrine in rats. |
| Q40575964 | Characterisation of artemisinin-chloroquinoline hybrids for potential metabolic liabilities |
| Q41912557 | Characterization of the chloroquine-induced mouse model of pruritus using an automated behavioural system. |
| Q91958492 | Chloroquine as prophylactic agent against COVID-19? |
| Q37674854 | Chloroquine use improves dengue-related symptoms |
| Q37056580 | Clinical pharmacology of artemisinin-based combination therapies |
| Q33686633 | Comparative analysis of the safety and tolerability of fixed-dose artesunate/amodiaquine versus artemether/lumefantrine combinations for uncomplicated falciparum malaria in pregnancy: a randomized open label study |
| Q54247222 | Comparative effectiveness of malaria prevention measures: a systematic review and network meta-analysis. |
| Q28468549 | Concurrent Inflammation Augments Antimalarial Drugs-Induced Liver Injury in Rats |
| Q35782842 | Confirmed Plasmodium vivax Resistance to Chloroquine in Central Vietnam |
| Q37735182 | Current knowledge and challenges of antimalarial drugs for treatment and prevention in pregnancy |
| Q47930777 | Cytogenetic and oxidative status of human lymphocytes after exposure to clinically relevant concentrations of antimalarial drugs atovaquone and proguanil hydrochloride in vitro |
| Q41930137 | Differences in anti-malarial activity of 4-aminoalcohol quinoline enantiomers and investigation of the presumed underlying mechanism of action |
| Q40298440 | Different doses of amodiaquine and chloroquine for treatment of uncomplicated malaria in children in Guinea-Bissau: implications for future treatment recommendations |
| Q35006418 | Discovery, mechanisms of action and combination therapy of artemisinin |
| Q48438901 | Dopamine levels modulate the updating of tastant values |
| Q58392274 | Drug development for use during pregnancy: impact of the placenta |
| Q24241218 | Drugs for treating uncomplicated malaria in pregnant women |
| Q24246287 | Drugs for treating uncomplicated malaria in pregnant women |
| Q37272095 | Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial |
| Q37962462 | Effects of artemisinins on reticulocyte count and relationship to possible embryotoxicity in confirmed and unconfirmed malarial patients |
| Q34246881 | Effects of nanoliposomal and pegylated nanoliposomal artemisinin in treatment of breast cancer |
| Q48006398 | Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine |
| Q28297711 | Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial |
| Q34646141 | Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review |
| Q36398987 | Efficacy and safety of artesunate plus amodiaquine in routine use for the treatment of uncomplicated malaria in Casamance, southern Sénégal |
| Q36561097 | Efficacy and tolerability of a new formulation of artesunate-mefloquine for the treatment of uncomplicated malaria in adult in Senegal: open randomized trial |
| Q41946358 | Efficacy of chloroquine-proguanil malaria prophylaxis in a non-immune population in Bangui, Central African Republic: a case-control study. |
| Q38027179 | Emerging drugs for malaria |
| Q34374622 | Enantiomerically pure amino-alcohol quinolines: in vitro anti-malarial activity in combination with dihydroartemisinin, cytotoxicity and in vivo efficacy in a Plasmodium berghei mouse model |
| Q34177472 | Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination |
| Q28542069 | Ethics, economics, and the use of primaquine to reduce falciparum malaria transmission in asymptomatic populations |
| Q51641836 | Exploring an animal model of amodiaquine-induced liver injury in rats and mice. |
| Q35183422 | Exposure to anti-malarial drugs and monitoring of adverse drug reactions using toll-free mobile phone calls in private retail sector in Sagamu, Nigeria: implications for pharmacovigilance |
| Q36446234 | Feasibility and acceptability of injectable artesunate for the treatment of severe malaria in the Democratic Republic of Congo |
| Q38550008 | Ferroquine and its derivatives: new generation of antimalarial agents. |
| Q38558100 | Fosmidomycin as an antimalarial drug: a meta-analysis of clinical trials |
| Q39591248 | High residual chloroquine blood levels in African children with severe malaria seeking healthcare |
| Q28474365 | High risk of severe anaemia after chlorproguanil-dapsone+artesunate antimalarial treatment in patients with G6PD (A-) deficiency |
| Q37827403 | Hydroxychloroquine: from malaria to autoimmunity |
| Q36171691 | Identification of (+)-erythro-mefloquine as an active enantiomer with greater efficacy than mefloquine against Mycobacterium avium infection in mice |
| Q33892018 | Idiosyncratic quinoline central nervous system toxicity: Historical insights into the chronic neurological sequelae of mefloquine |
| Q37991390 | Immunomodulatory effects of antimicrobial agents. Part II: antiparasitic and antifungal agents |
| Q33826283 | In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals |
| Q46471530 | Influence of mefloquine administration during early pregnancy on rat embryonic development |
| Q24809091 | Intermittent presumptive treatment for malaria |
| Q36316144 | Intermittent preventive treatment for the prevention of malaria during pregnancy in high transmission areas |
| Q21032450 | Intermittent preventive treatment of malaria in pregnant women and infants: making best use of the available evidence |
| Q63248437 | Late Neurological Consequences of Zika Virus Infection: Risk Factors and Pharmaceutical Approaches |
| Q34529355 | Limited ability of Plasmodium falciparum pfcrt, pfmdr1, and pfnhe1 polymorphisms to predict quinine in vitro sensitivity or clinical effectiveness in Uganda |
| Q56383949 | Malaria |
| Q37056675 | Malaria and oral health |
| Q36832446 | Malaria chemotherapeutics part I: History of antimalarial drug development, currently used therapeutics, and drugs in clinical development |
| Q56342519 | Malaria control and chemoprophylaxis policy in the Republic of Korea Armed Forces for the previous 20 years (1997-2016) |
| Q33370139 | Malaria: diagnosis and treatment of falciparum malaria in travelers during and after travel |
| Q37290599 | Management of relapsing Plasmodium vivax malaria |
| Q35725379 | Medicinal plants used by various tribes of bangladesh for treatment of malaria |
| Q41549946 | Mefloquine and Its Enantiomers Are Active against Mycobacterium tuberculosis In Vitro and in Macrophages |
| Q36919426 | Mefloquine exerts anticancer activity in prostate cancer cells via ROS-mediated modulation of Akt, ERK, JNK and AMPK signaling |
| Q36919343 | Mefloquine induces cell death in prostate cancer cells and provides a potential novel treatment strategy in vivo |
| Q36375160 | Mefloquine inhibits chondrocytic proliferation by arresting cell cycle in G2/M phase |
| Q40433562 | Mefloquine-induced eosinophilic pneumonia |
| Q36572637 | Minimising the potential for metabolic activation in drug discovery |
| Q46250415 | More insights into the pharmacological effects of artemisinin |
| Q39772977 | New 1-aryl-3-substituted propanol derivatives as antimalarial agents |
| Q22061804 | New Fixed-Dose Artesunate-Mefloquine Formulation against Multidrug-Resistant Plasmodium falciparum in Adults: a Comparative Phase IIb Safety and Pharmacokinetic Study with Standard-Dose Nonfixed Artesunate plus Mefloquine |
| Q57013585 | Other 4-Methanolquinolines, Amyl Alcohols and Phentathrenes: Mefloquine, Lumefantrine and Halofantrine |
| Q38653146 | Ototoxicity (cochleotoxicity) classifications: A review |
| Q36140676 | Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome |
| Q41937695 | Pharmacodynamics of antimalarial chemotherapy |
| Q34020238 | Pharmacogenetics of antimalarial drugs: effect on metabolism and transport |
| Q36161252 | Pharmacotherapy, vaccines and malaria advice for HIV-infected travellers |
| Q41933350 | Phase I randomized dose-ascending placebo-controlled trials of ferroquine--a candidate anti-malarial drug--in adults with asymptomatic Plasmodium falciparum infection |
| Q37585062 | Plant-derived antimalarial agents: new leads and efficient phytomedicines. Part II. Non-alkaloidal natural products. |
| Q34678568 | Plasmodium drug targets outside the genetic control of the parasite |
| Q49791979 | Population Pharmacokinetic properties of Sulfadoxine and Pyrimethamine: A pooled analysis to Inform Optimal Dosing in African Children with Uncomplicated Malaria |
| Q55315206 | Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions. |
| Q28469316 | Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate |
| Q41912856 | Primaquine in Plasma and Methemoglobinemia in Patients with Malaria Due to Plasmodium vivax in the Brazilian Amazon Basin |
| Q36406218 | Problem pathogens: prevention of malaria in travellers |
| Q27314913 | Prolonged antigen presentation is required for optimal CD8+ T cell responses against malaria liver stage parasites |
| Q35211841 | Prolonged elevation of viral loads in HIV-1-infected children in a region of intense malaria transmission in Northern Uganda: a prospective cohort study |
| Q47992600 | Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2). |
| Q36895758 | Prospects for the treatment of drug-resistant malaria parasites. |
| Q33935263 | Protection from anthrax toxin-mediated killing of macrophages by the combined effects of furin inhibitors and chloroquine. |
| Q26743363 | Psychiatric effects of malaria and anti-malarial drugs: historical and modern perspectives |
| Q34138808 | Psychiatric side effects of non-psychiatric drugs |
| Q64903331 | Psychosis consequent to antimalarial drug use in a young child. |
| Q35024655 | Psychosis with paranoid delusions after a therapeutic dose of mefloquine: a case report |
| Q36338815 | Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans |
| Q37531333 | Quinine monotherapy for treating uncomplicated malaria in the era of artemisinin-based combination therapy: an appropriate public health policy? |
| Q28469106 | Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers |
| Q31150958 | Rectal artemisinins for malaria: a review of efficacy and safety from individual patient data in clinical studies |
| Q21032454 | Respiratory Manifestations of Malaria |
| Q36834343 | Review of intermittent preventive treatment for malaria in infants and children |
| Q33898575 | Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs |
| Q52562304 | Safety Experience During Real-World Use of Injectable Artesunate in Public Health Facilities in Ghana and Uganda: Outcomes of a Modified Cohort Event Monitoring Study (CEMISA) |
| Q95297415 | Safety considerations of chloroquine and hydroxychloroquine in treatment of COVID-19 |
| Q37738205 | Scaling up of intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine: prospects and challenges |
| Q41912660 | Serious psychiatric symptoms after chloroquine treatment following experimental malaria infection |
| Q33935493 | Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria |
| Q41940289 | Spontaneous adverse drug reaction reporting in Rural Districts of Mozambique |
| Q38245842 | Strategic use of antimalarial drugs that block falciparum malaria parasite transmission to mosquitoes to achieve local malaria elimination |
| Q33613450 | Structural basis for inhibition of histamine N-methyltransferase by diverse drugs |
| Q36130640 | Synthesis and evaluation of naphthyridine compounds as antimalarial agents |
| Q37108386 | TSCQ study: a randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trial |
| Q36802630 | Tafenoquine: a promising new antimalarial agent |
| Q28534608 | Targeting asymptomatic malaria infections: active surveillance in control and elimination |
| Q47891747 | The Effects of Quinine on Neurophysiological Properties of Dopaminergic Neurons. |
| Q28551177 | The Interactions of P-Glycoprotein with Antimalarial Drugs, Including Substrate Affinity, Inhibition and Regulation |
| Q42616839 | The anti-malarial drug Mefloquine disrupts central autonomic and respiratory control in the working heart brainstem preparation of the rat. |
| Q41954441 | The antimalarial drug quinine disrupts Tat2p-mediated tryptophan transport and causes tryptophan starvation |
| Q37453950 | The antimalarial drug quinine interferes with serotonin biosynthesis and action |
| Q36013753 | The antimalarial drugs quinine, chloroquine and mefloquine are antagonists at 5-HT3 receptors. |
| Q35930447 | The complexities of malaria disease manifestations with a focus on asymptomatic malaria |
| Q37346189 | The neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria |
| Q37928680 | The pharmacogenetics of antimalaria artemisinin combination therapy |
| Q37879203 | Therapy of vector-borne protozoan infections in nonendemic settings |
| Q33880614 | Tolerability and efficacy of a pediatric granule formulation of artesunate-mefloquine in young children from Cameroon with uncomplicated falciparum malaria |
| Q37272811 | Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers |
| Q41769139 | Topical dihydroartemisinin inhibits suture-induced neovascularization in rat corneas through ERK1/2 and p38 pathways |
| Q28253420 | Toxicity evaluation of artesunate and artelinate in Plasmodium berghei-infected and uninfected rats |
| Q37693152 | Toxicity of the antimalarial artemisinin and its dervatives. |
| Q38263357 | Transcriptional profiling of reactive metabolites for elucidating toxicological mechanisms: a case study of quinoneimine-forming agents |
| Q44083782 | Trapped in misbelief for almost 40 years: selective synthesis of the four stereoisomers of mefloquine |
| Q37053822 | Treatment and prevention of malaria in pregnancy and newborn |
| Q48036116 | Treatment and prevention of malaria in pregnancy: opportunities and challenges. |
| Q40352841 | Two Novel Calcium-Dependent Protein Kinase 1 Inhibitors Interfere with Vertical Transmission in Mice Infected with Neospora caninum Tachyzoites. |
| Q92089633 | Unconventional secretory pathway activation restores hair cell mechanotransduction in an USH3A model |
| Q34630304 | pH-responsive artemisinin derivatives and lipid nanoparticle formulations inhibit growth of breast cancer cells in vitro and induce down-regulation of HER family members |
Search more.